Loading
Latest filing published 16 Sept 2026 for Ange Prostatype Genomics AB, €49k. Read the official filing
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
No signal scores available.
This profile gathers the share dealings of Håkan Englund in Ange Prostatype Genomics AB. The record holds 2 filings, all for trades on 15 September 2026.
No open-market purchase or sale appears among the filings, only grants, plan transactions and other operations. Such operations are usually part of compensation schedules, which makes them a weaker signal than an open-market trade.
On 16 September 2026 came the latest disclosure, a transaction for €49k in Ange Prostatype Genomics AB. Source: insider filings from Finansinspektionen. Past trades are no guide to future returns.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
2 of 2 declarations